Regulator of G protein signaling (RGS) proteins accelerate the endogenous GTPase activity of G␣ i/o proteins to increase the rate of deactivation of active G␣-GTP and G␤␥ signaling molecules. Previous studies have suggested that RGS proteins are more effective on less efficiently coupled systems such as with partial agonist responses. To determine the role of endogenous RGS proteins in functional responses to -opioid agonists of different intrinsic efficacy, G␣ i/o subunits with a mutation at the pertussis toxin (PTX)-sensitive cysteine (C351I) and with or without a mutation at the RGS binding site (G184S) were stably expressed in C6 glioma cells expressing a -opioid receptor. Cells were treated overnight with PTX to inactivate endogenous G proteins. Maximal inhibition of forskolin-stimulated adenylyl cyclase by the low-efficacy partial agonists buprenorphine and nalbuphine was increased in cells expressing RGS-insensitive G␣ o CIGS , G␣ i2 CIGS , or G␣ i3 CIGS compared with their G␣ CI counterparts, but the RGS-insensitive mutation had little or no effect on the maximal inhibition by the higher efficacy agonists DAMGO and morphine. The potency of all the agonists to inhibit forskolin-stimulated adenylyl cyclase was increased in cells expressing RGS-insensitive G␣ o CIGS , G␣ i2 CIGS , or G␣ i3 CIGS , regardless of efficacy. These data are comparable with predictions based on a collision coupling model. In this model, the rate of G protein inactivation, which is modulated by RGS proteins, and the rate of G protein activation, which is affected by agonist intrinsic efficacy, determine the maximal agonist response and potency at adenylyl cyclase under steady state conditions.
sivity and the numbers of molecules), receptor occupancy, and agonist intrinsic efficacy (Whaley et al., 1994; Krumins et al., 1997) . The inactivation rate constant is dependent on the rate of GTP hydrolysis, which is modulated by RGS proteins, thus providing a simple model for predicting the effects of RGS proteins on agonist responses.
In this study, we tested the hypothesis that endogenously expressed RGS proteins affect maximal agonist response and potency in a manner consistent with the collision coupling model and that this explains the differential sensitivity of full and partial agonists to RGS action. Moreover, because different G␣ i/o subtypes may have different rate constants for activation and inactivation by agonist-occupied receptors and RGS proteins may differentially affect the G␣ subtypes because of their different GAP activities (Posner et al., 1999; Posner et al., 1999; Cavalli et al., 2000; Welsby et al., 2002; Hooks et al., 2003) , we also test the hypothesis that the endogenous RGS proteins may be more effective at G␣ o than the G␣ i subtypes.
By expressing G␣ i/o subunits with a mutation at the pertussis toxin (PTX)-sensitive cysteine (C351I) in C6 glioma cells expressing the -opioid receptor, we are able to study the action of the exogenously expressed G␣ subtype on inhibition of adenylyl cyclase after treatment with PTX to uncouple the endogenous G␣ subunits. There is evidence for the expression of certain RGS proteins in C6 cells (Snow et al., 2002) , but a full description is not available. Therefore, to examine the effects of the GAP activity of the total complement of endogenous RGS proteins present in C6 cells, we expressed the PTX-insensitive G␣ subunits with or without an additional mutation at the RGS binding site (G184S). This prevents binding between G␣ and the RGS box of all RGS proteins without affecting the endogenous GTPase activity of the G␣. This eliminates RGS-stimulated GTPase-activity (Clark et al., 2003; Huang et al., 2006) , resulting in an accumulation of active G␣-GTP and G␤␥ signaling molecules, which is observed as an increase in agonist potency and/or an increase in the maximal agonist effect (Clark et al., 2003) .
Our results demonstrate that, as predicted by the collision coupling model, endogenous RGS proteins have a greater effect on the maximal effect of partial -opioid agonists than full agonists at inhibition of adenylyl cyclase but similarly reduce agonist potency for both full and partial agonists.
Materials and Methods

Materials. [
3 H]Diprenorphine and [ 35 S]GTP␥S were purchased from PerkinElmer Life and Analytical Sciences (Waltham, MA). Tissue culture medium, fetal bovine serum, trypsin, LipofectAMINE Plus reagent, LipofectAMINE 2000, G-418 (Geneticin) , and Zeocin were from Invitrogen (Carlsbad, CA). Trizma, GDP, forskolin, 3-isobutyl-1-methylxantihine (IBMX), DAMGO, and other biochemicals were from Sigma Chemical Co (St. Louis, MO). Morphine, buprenorphine, nalbuphine, and naloxone were obtained through the Opioid Basic Research Center at the University of Michigan (Ann Arbor, MI).
RGS-Insensitive Mutation and FLAG-Epitope Tagging. Human G␣ containing a cysteine-to-isoleucine mutation at the PTX-sensitive Cys (G␣ oA C351I , G␣ i2 C352I , G␣ i3 C351I ) in the pcDNA3.1ϩ vector were purchased from the Missouri University of Science and Technology cDNA Resource Center (http://www.cdna.org). For insertion into the Zeocin-resistant vector, pcDNAzeo Ϫ , the restriction enzymes Nhe I and Xba I (Promega, Madison, WI) were used to remove G␣ oA C351I or G␣ i3 C351I from the original vector and Pme I (New England Biolabs, Ipswich, MA) was used for G␣ i2 C352I , followed by ligation with calf intestinal alkaline phosphatase-treated pcDNAzeo Ϫ vector. A QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) was used to replace the glycine at the RGS binding site (G␣ o A, G␣ i2 : G184S; G␣ i3 : G183S) to a serine using the following primers: 5Ј-GGGTCA-AAACCACTTCCATCGTAGAAAC-3Ј for G␣ oA   C351I   , 5Ј-GTAAAGACC-ACGTCGATCGTGGAG-3Ј for G␣ i2   C352I , and 5Ј-CGAGAGTGAAGA-CCACATCCATTGTAGAAAC-3Ј for G␣ i3 C351I (underlining indicates mutation sites).
A FLAG tag was added to the N terminus of PTX-insensitive G␣ in the Zeocin-resistant vector using the QuikChange sitedirected mutagenesis kit with the following primers: for G␣ oA C351I , 5Ј-CCCTTGATCGGTACCACCATGGACTACAAAGACGATGACGA-CAAG-ATGGGATGTACTCTG-3Ј; for G␣ i2 C352I , 5Ј-CCCTTGATCGGT-ACCACCATGGACTACAAAGACGATGACGACAAG-ATGGGCT GC-ACCGTG-3Ј; and for G␣ i3 C351I 5Ј-CCCTTGATCGGTACCACCATG-GACTACAAAGACGATGACGACAAG-ATGGGCTGCACGTTG-3Ј.
Cell Culture and Expression of PTX-Insensitive G␣. Human -opioid receptor in the pcDNA3.1 vector (http://www.cdna.org) was stably transfected into HEK293 cells using LipofectAMINE 2000 and selected using 0.8 mg/ml G-418. C6 cells stably expressing the -opioid receptor (C6; Emmerson et al., 1996) or HEK293 cells stably expressing the -opioid receptor (HEK293) were stably transfected with PTX-insensitive G␣ using LipofectAMINE Plus and selected using 0.4 mg/ml Zeocin for C6 or 0.2 mg/ml Zeocin for HEK293. Selected clones were maintained in DMEM containing 10% fetal bovine serum, 0.4 mg/ml (HEK293) or 0.25 mg/ml (C6) G-418, and 0.2 mg/ml (HEK293) or 0.4 mg/ml (C6) Zeocin.
Membrane Preparation. Cells were treated overnight with 100 ng/ml PTX before harvesting and preparation of plasma membranes as described previously (Clark et al., 2003) .
Western Blots. Membrane proteins (5 g of HEK293-FLAGG␣ CI ; 60 g of C6G␣ CI/CIGS ) were separated by 12% SDS-polyacrylamide gel electrophoresis (Protogel; National Diagnostics, Inc., Atlanta, GA) and transferred to a nitrocellulose membrane (45 m; Pierce, Rockford, IL). Membranes with C6 G␣ CI/CIGS were blocked overnight with 5% dry milk and probed with 1:200 anti-G␣ o (Santa Cruz Biotechnology, Santa Cruz, CA) or 1:6000 anti-G␣ i2 (Calbiochem, San Diego, CA), followed by 1:15,000 goat anti-rabbit IgG-HRP in 5% dry milk (Santa Cruz Biotechnology). Membranes with HEK293-FLAGG␣ CI were blocked overnight with 5% dry milk and probed with 1:2000 anti-M2 FLAG and 1:1000 anti-tubulin (Sigma Chemical Co., St. Louis, MO) in 5% dry milk followed with 1:12,000 goat anti-mouse IgG-HRP in 5% dry milk (Santa Cruz Biotechnology). Bands were visualized using Super Signal West Pico enhanced chemiluminescence (Pierce) and quantified using a KODAK Image Station (Carestream Health, Rochester, NY). We were unable to find a satisfactory antibody to a region of G␣ i3 without the PTX-or RGS-insensitive mutations.
Receptor Binding Assay. Membranes (5-20 g) were incubated with 2 to 3 nM [ 3 H]diprenorphine with or without 50 M naloxone (to determine nonspecific binding) in 50 mM Tris-HCl, pH 7.4, as described previously (Clark et al., 2003) , to determine receptor number.
[ 35 S]GTP␥S Binding Assay. Membranes (5-20 g) were incubated for 60 min with 0.1 nM [
35 S]GTP␥S, 30 M GDP, 100 mM NaCl, 5 mM MgCl 2 ,1 mM dithiothreitol, 20 mM Tris-HCl, pH 7.4, and 0.01 to 10 M DAMGO or distilled water and filtered as described previously (Clark et al., 2003) to determine bound
cAMP Accumulation Assay. Cells were plated to ϳ80% confluence 2 days before the assay and treated with 100 ng/ml PTX. To start the assay, medium was replaced with DMEM containing 5 M forskolin, 1 mM IBMX, and 0.001 to 10 M DAMGO, morphine, nalbuphine, buprenorphine, or distilled water. After 10 min at 37°C, the reaction was stopped by replacing the medium with ice-cold 3% perchloric acid. After at least 30 min at 4°C, 0.4 ml was removed from each sample, neutralized with 0.08 ml of 2.5 M KHCO 3 , vortexed, and centrifuged at 15,000g for 1 min. A 20-l aliquot was taken from 
Results
Collision Coupling Model Predictions of Maximal
Agonist Response and Potency with and without RGS Proteins. The prediction of the collision coupling model for the maximum agonist response at an effector, f, is
where k a is the rate constant for activation, R TOT is the total number of receptors, f active is the fraction of bound receptors in the active form (a measure of agonist intrinsic efficacy), and k hydrol is the rate constant for hydrolysis of G␣-GTP (Kinzer-Ursem et al., 2006; see Appendix for details). For simplicity of notation, we define an overall activation rate constant k act as:
Thus, the activation level of the effector (maximal response) is determined by the overall activation rate constant k act and the hydrolysis rate constant k hydrol . To predict the effect of RGS proteins on the maximum agonist response, we used the estimated values for rate constants of hydrolysis (k hydrol ) of 0.1 s Ϫ1 in the absence of RGS proteins and 5 s Ϫ1 in the presence of RGS proteins (Shea et al., 2000) . The value of the rate constant for activation, k a , can be estimated from Monte Carlo simulations of receptor and G protein diffusion to be on the order of 10 Ϫ5 to 10 Ϫ3 (number per cell) Ϫ1 s Ϫ1 (Mahama and Linderman, 1994; Shea et al., 1997) and the units of R TOT are (number per cell). Values for maximal response were calculated for a range of values for the overall activation rate constant (k act ) (Fig. 1) . When k hydrol is small relative to k act , then agonist response approaches 100% and when k hydrol is larger relative to k act , then agonist effect approaches zero. Thus, the model predicts that RGS proteins will reduce agonist response most effectively when k hydrol is similar to k act . Partial agonists have previously been shown to have slower activation rates than full agonists due to the activation of fewer receptors (Traynor et al., 2002) . Therefore, the model predicts that RGS proteins will have less effect on the maximal effect of full agonists than partial agonists.
The prediction of the collision coupling model for potency is
(see Appendix for details). The effect of RGS proteins on agonist potency is predicted using the estimated values for rates of inactivation (k hydrol ) of 0.1 s Ϫ1 in the absence of RGS proteins and 5 s Ϫ1 in the presence of RGS proteins. Values for potency (EC 50 ) were calculated for a K d of 250 nM with a range of values for the overall activation rate constant (k act ) (Fig. 2) . This model predicts that RGS proteins will reduce potency (increase EC 50 ) across a wide range of k act values, but when k act is small relative to k hydrol , which would occur for example with a very-low-efficacy agonist, then EC 50 approaches the K d and RGS proteins will have diminished effect on agonist potency. Therefore, the potency of full agonists could be expected to be decreased by RGS proteins similarly to or more than partial agonists, depending on the rate of activation. To test this model, we have studied RGS modulation of -opioid inhibition of adenylyl cyclase. Because we do not know which RGS proteins are involved in opioid inhibition of adenylyl cyclase and there are no inhibitors of RGS proteins available, we have made use of RGS-insensitive G␣ i/o proteins to prevent all RGS protein activity. To avoid a potential confound due to effects of receptor and G protein levels, we have compared sets of clones expressing similar levels of receptor and similar levels of PTX-insensitive G␣ with or without RGS sensitivity.
G␣ Expression Levels and [ 35 S]GTP␥S Binding. Treatment of C6 cells with 100 ng/ml PTX overnight has been shown to inactivate the endogenous G␣ i/o (Clark et al., 2003 so that only the activity of the exogenously expressed PTX-insensitive G␣ i/o may be examined. In this study, all cells were treated overnight with PTX to uncouple endogenous G␣ i/o from the receptors. C6 glioma cells stably expressing the -opioid receptor (C6) and either PTX-insensitive G␣ CI , or PTX-and RGS-insensitive G␣ CIGS were selected for similar G␣ expression levels ( Fig. 3 ) and receptor expression levels ( Table 1 ), so that the rate of G protein activation will be affected only by agonist intrinsic efficacy and concentration. Levels of expression of different G␣ i/o mutants within a G␣ i/o subtype and identified by the same antibody can be compared across clones, but comparisons cannot be made across G␣ i/o subtypes. In addition, C6 cells express mainly G␣ i2 and little G␣ o (Charpentier et al., 1993) , so the antibody recognizes both the endogenous G␣ i2 and the transfected G␣ i2 , making quantification by Western blot difficult. Therefore, we also compared maximal levels of DAMGO-stimulated [
35 S]GTP␥S binding, which correlates with the level of functional G␣ expression . DAMGO stimulated a large maximal increase in [
35 S]GTP␥S binding in membranes from cells expressing the mutant G␣ i2 or G␣ o proteins confirming a significant level of expression, although slightly lower than that seen in wild-type cells (Table 1) . It is noteworthy that DAMGO-stimulated [
35 S]GTP␥S binding was the same in both RGS-sensitive and -insensitive clones matched for G␣ i2 or G␣ o levels supporting the Western blot data. G␣ i3 CI or G␣ i3 CIGS did not express well in the C6 cells, but the set of matched clones with similar receptor levels gave low maximal levels of DAMGO-stimulated [ 35 S]GTP␥S binding (Table 1) . There is the possibility that factors other than G␣ expression and receptor levels could differ between the clones, most pertinently the level and type of RGS proteins. This is difficult to assess because of the large number of known RGS proteins. However, our method compares clones expressing the same G␣ subtype that is CI or G␣ o CI with or without the RGS-insensitive mutation (GS) and subjected to Western blot analysis as described under Materials and Methods. Shown is the mean intensity of each band(s) relative to the intensity of the band(s) for the untransfected cells performed on the same blot (n ϭ 3). Representative blots for G␣ i2 and G␣ o are shown. Note that C6 cells endogenously express mainly G␣ i2 (Charpentier et al., 1993) . CI expressing cells (Table 1) . This has been demonstrated previously .
-Opioid Agonist Inhibition of Forskolin-Stimulated cAMP Accumulation. Maximal inhibition of 5 M forskolin-stimulated cAMP accumulation by the full agonist, DAMGO, was significantly higher with the RGS-insensitive mutation in the cells expressing either matched pair of G␣ i2 CI and G␣ i2 CIGS (Fig. 4 , Table 2 ). The potency of DAMGO to inhibit forskolin-stimulated cAMP accumulation was also increased (Fig. 4) . The potency and efficacy of DAMGO to stimulate [
35 S]GTP␥S binding in the matched G␣ i2 CI and G␣ i2 CIGS clones were the same (Table 1) , which confirms an effect of endogenous RGS proteins in decreasing the concentration of the active G␣-GTP. In contrast, in cells expressing G␣ o CI or G␣ o CIGS , the maximal inhibition of forskolin-stimulated cAMP accumulation by DAMGO was not affected by the RGS-insensitive mutation (Fig. 4c) . The potency of DAMGO, however, was increased by the RGS-insensitive mutation in G␣ o CI -expressing cells (Fig. 4c) . Likewise, the RGS-insensitive mutation increased DAMGO potency in cells expressing G␣ i3
CI without affecting maximal inhibition of forskolinstimulated cAMP accumulation (Fig. 4d) . The increase in DAMGO potency with or without an increase in maximal response with the RGS-insensitive mutation agrees with the predictions based on the collision coupling model under conditions of a fast k act . Although the cells were matched within G␣ subtypes, there was a difference in the level of forskolinstimulated cAMP between the matched RGS-sensitive and -insensitive clones, which was especially noticeable for clones Fig. 4 . DAMGO inhibition of forskolin-stimulated adenylyl cyclase. C6 cells stably expressing PTX-insensitive G␣ were plated onto 24-well plates and treated with 100 ng/ml PTX for 2 days before assay. The media was replaced with serum-free DMEM containing 5 M forskolin, 1 mM IBMX, and 0 to 10 M DAMGO to start the assay, which was allowed to proceed for 10 min at 37°C before termination by replacing the assay media with 3% perchloric acid. Accumulation of cAMP was measured as described under expressing lower levels of the mutant G␣ i2 proteins (Fig. 4b) and clones expressing the mutant G␣ o (Fig. 4c) . This may relate to an increased adenylyl cyclase sensitization in the presence of the more efficient G␣ signaling . Consequently, we repeated the experiment in cells expressing mutant G␣ i2 cells in the presence of fetal bovine serum in the assay medium to prevent expression of sensitization . Under these conditions, the level of forskolin-stimulated cAMP accumulation in the G␣ i2 CI/B and G␣ i2 CIGS/B clones was similar (1.38 Ϯ 0.11 and 0.98 Ϯ 0.15 pmol/mg of protein, respectively), but the maximal degree of inhibition by DAMGO (34 Ϯ 8 and 85 Ϯ 2%, respectively) and potencies (14 Ϯ 9 and 1.4 Ϯ 0.3 nM, respectively) were unchanged compared with conditions in which the level of forskolin-stimulated cAMP was widely different (Table 2 ). In confirmation of this, G␣ o CI and G␣ o CIGS clones that gave a similar level of forskolin-stimulated cAMP gave similar DAMGO-mediated degree of inhibition but retained the shift in potency (see legend to Fig. 4c ). In addition, the maximal DAMGO inhibition was not dependent on the forskolin concentration, for example, with the G␣ i2 CI/B clone, maximal DAMGO inhibition was similar (31 Ϯ 9%) using 30 M forskolin as with 5 M forskolin (37%; Table 2 ).
To further examine the model experimentally, relative agonist response was determined for partial agonists providing lower k act values as a percentage of the maximal DAMGO inhibition in the same assay. The relative efficacy of morphine, which behaved as a full agonist in these experiments, was not significantly affected by the RGS-insensitive mutation in cells expressing G␣ o CI , G␣ i2 CI , or G␣ i3 CI (Fig. 5) . On the other hand, the relative response of the partial agonists, buprenorphine and nalbuphine, was increased by 1.3-and 1.9-fold, respectively, in the RGS-insensitive mutation in the G␣ i2 CI -expressing cells, 1.3-and 2.6-fold in the RGS-insensitive G␣ o CI -expressing cells, and 2.3-and 6.7-fold in the G␣ i3 CI -expressing cells (Fig. 5) . The potencies of morphine and buprenorphine were also increased by the RGS-insensitive mutation in each of the G␣ subtypes (Table 2) . These increased potencies and maximal responses with the RGSinsensitive mutation agree with the predictions of the collision coupling model under conditions of slower k act .
The potency of the partial agonist with the lowest intrinsic efficacy, nalbuphine, was decreased rather than increased by the RGS-insensitive mutation. It may be speculated that when the k act becomes so slow, steady-state conditions are not reached, so the determined EC 50 is high. To test this, we repeated the cAMP accumulation assay with nalbuphine using an incubation of 30 min rather than 10 min to allow steady state to be reached. This reversed the shift in potency of nalbuphine to give the expected increase with the RGSinsensitive mutation (Table 2) , although under these longer assay conditions, nalbuphine was less potent. As with the shorter period, maximal inhibition by nalbuphine compared with DAMGO was higher with the RGS-insensitive G␣ o CIGS (92 Ϯ 5% of DAMGO) than with the RGS-sensitive G␣ o CI (68 Ϯ 5% of DAMGO). However, over the longer assay period, the maximal inhibition by DAMGO was lower with the RGSinsensitive G␣ o CIGS (69 Ϯ 3% inhibition) than with the RGSsensitive G␣ o CI (85 Ϯ 5% inhibition).
Calculations of Overall Activation Rate Constants.
The RGS-insensitive G␣ subunits do not bind RGS proteins, so the rate constant of inactivation (k hydrol ) for these G␣ subunits will be the same as if there were no RGS proteins present. Using this assumption, we used the collision coupling model to calculate the overall activation rate constants (k act ) for the RGS-insensitive clones using the experimental EC 50 values for DAMGO inhibition of adenylyl cyclase (Table  2) , a rate constant of inactivation of 0.1 s Ϫ1 (k hydrol ), and K i values measured in the presence of NaCl and GDP (from Emmerson et al., 1996) for the K d values. These values are presented in Table 3 . As predicted by the model, the calculated k act for DAMGO was slower with decreased receptor number in the clones expressing the same G␣ subtype. When matched for receptor number, the k act for DAMGO was almost 2-fold faster with G␣ o CIGS than with G␣ i2 CIGS . In agreement with the collision coupling concept of lower agonist intrinsic efficacy reducing the number of active receptors, and therefore productive "collisions," the overall activation rate constants (k act ) for the partial agonist, morphine, were 
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at ASPET Journals on June 22, 2017 molpharm.aspetjournals.org at least 7 times slower than for DAMGO at each of the RGS-insensitive clones. However, k act values could not be calculated for nalbuphine or buprenorphine because the EC 50 values were higher than the K i value measured in the presence of NaCl and GDP (Emmerson et al., 1996) .
[ 35 S]GTP␥S Binding and cAMP Accumulation Using FLAG-Tagged G␣ o CI , G␣ i2 CI , and G␣ i3 CI . To determine whether the faster rates of activation calculated for the G␣ o CIGS cells were due to higher levels of expression, G␣ subunits were FLAG-tagged at the N terminus so that expression levels of different G␣ subtypes could be directly compared by Western blot using the same anti-FLAG antibody. FLAG-G␣ i2 CI , FLAG-G␣ o CI , or FLAG-G␣ i3 CI were stably expressed in HEK293 cells stably expressing the -opioid receptor, and clones expressing similar levels of receptor and FLAG-G␣ were selected (Fig. 6, a and b) . None of the FLAG-G␣ i3 CI clones expressed higher levels. Maximal stimulation of [
35 S]GTP␥S binding by DAMGO after overnight treatment with PTX was 3-fold higher in the FLAG-G␣ o CI -expressing clone than in the FLAG-G␣ i2 CI or FLAG-G␣ i3 CI clones (Fig.  6c) . This suggests that the G␣ o CIGS cells used to calculate the rates of activation (Table 3 ) actually had lower levels of PTX-insensitive G␣ than the G␣ i2 CIGS clones because they had similar levels of stimulation of [
35 S]GTP␥S binding by DAMGO.
The degree of inhibition of forskolin-stimulated cAMP accumulation by DAMGO after overnight treatment with PTX was similar in the FLAG-G␣ o CI , FLAG-G␣ i2 CI , and FLAG-G␣ i3 CI clones (Fig. 6d ). These results demonstrate that higher levels of [
35 S]GTP␥S binding or faster rate constants of activation do not correlate with higher levels of inhibition of adenylyl cyclase.
Effect of Different G Protein Levels. The simple collision coupling model used here assumes that the G proteins are closely associated with adenylyl cyclase and that agonist potency is independent of G protein and adenylyl cyclase concentrations as shown in turkey erythrocyte membranes (Tolkovsky et al., 1982) . In this study, we used clones matched for receptor and G␣ protein levels to avoid the possible confound of transient G protein and adenylyl cyclase interactions. However, to determine whether G␣ and adenylyl cyclase are indeed precoupled, agonist potency at inhibition of forskolin-stimulated cAMP accumulation was compared in clones expressing different levels of FLAG-G␣ o CI but similar levels of -opioid receptor (Table 4) . DAMGO potency to inhibit cAMP accumulation was decreased at lower levels of FLAG-G␣ o CI expression, whereas potency to stimulate [ 35 S]GTP␥S binding was not affected, suggesting that G␣ and adenylyl cyclase are not precoupled in these cells. Relative -opioid agonist inhibition of forskolin-stimulated adenylyl cyclase. C6 cells stably expressing PTX-insensitive G␣ were plated onto 24-well plates and treated with 100 ng/ml PTX for 2 days before assay. cAMP accumulation was determined as described in legend to 
TABLE 3 Rates of activation calculated for cells expressing RGS-insensitive G␣ proteins
K act was calculated from the EC 50 for inhibition of forskolin-stimulated cAMP accumulation (equation 11). K i values measured in the presence of NaCl and GDP were used for K d (DAMGO K i ϭ 279 nM; morphine K i ϭ 132 nM; from Emmerson et al., 1996) and k hydrol ϭ 0.1 s Ϫ1 for absence of RGS proteins (from Shea et al., 2000) . 
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Comparison of Calculated and Experimentally Determined EC 50 Values. Using the calculated k act values for the RGS-insensitive clones and the k hydrol of 5 s Ϫ1 for the presence of RGS proteins, the expected decrease in potency for the RGS sensitive clones is predicted to range from 29-to 38-fold for DAMGO. This is higher than the experimental range of a 4-to 15-fold decrease in DAMGO potency across all of the RGS-sensitive clones compared with their matched RGS-insensitive clone ( Table 2 ). The predicted potency shift for morphine based on the k act values is 5-to 16-fold, which is closer to the measured range of a 2-to 6-fold decrease in morphine potency. In contrast, using previously published data comparing G␣ o CGGS and G␣ o CG (Clark et al., 2003) with the less efficiently coupled CG PTX-insensitive mutation (Bahia et al., 1998; , the measured 8-to 35-fold shift in DAMGO potency was similar to the 16-fold shift predicted from the calculated k act values of 2.1 and 2.3 s Ϫ1 . The measured morphine potency shift of 8-fold was also similar to the 3-to 6-fold shift predicted from the calculated k act values of 0.51 and 0.20 s Ϫ1 . This would suggest that rate constant of hydrolysis in the presence of RGS proteins of 5 s Ϫ1 , which was used for the predictions in this study, seems appropriate in these cells.
Discussion
This study, using RGS-insensitive mutants of G␣ proteins, demonstrates that endogenous RGS proteins reduce agonist potency for the inhibition of adenylyl cyclase similarly for full and partial agonists. The maximal agonist response, however, was reduced more by RGS proteins under conditions of slower rates of G protein activation, such as with partial agonists and was not affected by RGS proteins under conditions of faster rates of G protein activation, as with full agonists. These results agree with the predictions of a collision coupling model.
Agonist potency was increased similarly by the RGS-insensitive mutation for G␣ i2 -and G␣ o -expressing cells. Previous studies have shown that the rate of GTP hydrolysis is faster with G␣ o than with G␣ i2 with RGS4 (Posner et al., 1999; Cavalli et al., 2000; Hooks et al., 2003 ), or with RGS6, -7, -9, or -11 (Hooks et al., 2003 . There are several explanations for our finding. There could be RGS proteins present that do not act very efficiently as GAPS at G␣ o , or colocalization of the receptors and G proteins with the RGS proteins may be different. Although RGS proteins that might be considered as prime candidates to interact with -opioid signaling in vivo [i.e., RGS4 and RGS9 (Traynor and Neubig, 2005) ] are not expressed in C6 cells (Snow et al., 2002) , a number of RGS CI (11 Ϯ 2 fmol/mg), or FLAG-G␣ i3 CI (9 Ϯ 2 fmol/mg). d, maximal inhibition of forskolin-stimulated cAMP accumulation by 10 M DAMGO measured as described in legend to Fig. 4 . proteins have been identified (RGS 2, 8, 10, 12, and 14; Snow et al., 2002) , and several of these are known to effectively act as GAPS for G␣ i/o proteins coupled to -opioid receptors (reviewed in Xie and Palmer, 2005) . Finally, the PTX-insensitive G␣ CI mutants have faster rates of activation than wild-type G␣ (Bahia et al., 1998) , which may hide differences in the sensitivity of G␣ proteins to endogenous RGS proteins. Indeed, with the less efficiently coupled G␣ CG PTX-insensitive mutation, morphine is a partial agonist at inhibition of adenylyl cyclase (Clark et al., 2003) , whereas in this study with the G␣ CI PTX-insensitive mutation, morphine is a full agonist.
RGS Proteins and -Opioid
The increase in potency with the RGS-insensitive PTXinsensitive G␣ o CG was in accordance with the calculations based on the collision coupling model, whereas the potencies in the PTX-insensitive G␣ CI -expressing cells used in this study were not increased to the extent predicted. This may be due to a physical diffusion-controlled limitation on EC 50 and k act . This would limit the differences with and without RGS proteins in a highly efficient G␣ CI system with an already low EC 50 to less than the theoretical predictions (see Fig. 2 , inset). Alternatively, if RGS proteins do not modulate some of the G␣ CI pool, the effective k hydrol in the RGS sensitive cells would actually reflect a combination of k hydrol with and without RGS proteins, so the shift in potency with the G␣ CIGS mutant would be less than predicted.
The maximal effect of the full agonist DAMGO was increased in cells expressing RGS-insensitive G␣ i2 but not G␣ o or G␣ i3 proteins. This suggests that the k act for G␣ i2 is lower so that G␣ i2 is more susceptible to the effects of RGS proteins according to the collision coupling model. Using FLAGtagged G␣ subunits with similar expression levels, we measured a higher efficiency of coupling for G␣ o in the [ 35 S]GTP␥S assay, confirming that the -opioid receptor couples more efficiently to G␣ o and G␣ i3 than G␣ i2 (Remmers et al., 1999; Kimple et al., 2001) or G␣ i2 (Parker et al., 1991; Zhang et al., 2002) . This is also reflected in the higher basal steady state GTPase, which has been observed for G␣ o compared with G␣ i1 , G␣ i2 , or G␣ i3 (Hooks et al., 2003) . The endogenous basal rate of GTP hydrolysis, as measured by single turnover assay, has been shown to be similar for G␣ i2 and G␣ o (Posner et al., 1999) , supporting the suggestion that the faster steadystate GTPase rates for G␣ o are due to faster nucleotide exchange rates.
Although we see a more efficient coupling of the -opioid receptor with FLAG G␣ o than FLAG G␣ i2 or G␣ i3 , the degree of inhibition of forskolin-stimulated cAMP accumulation by DAMGO after overnight treatment with PTX was similar across the clones. The difference in the kinetics of the G␣ subtypes may not be sufficient to significantly affect the maximal response and potency of the full agonist. Alternatively, G␣ o could have a lower efficacy than G␣ i2 for inhibiting the adenylyl cyclases present in these cells, despite a faster rate of G protein activation. HEK293 cells are reported to contain ACI, ACIII, and ACVI; G␣ o has been shown to inhibit ACI but not ACVI, whereas G␣ i is able to inhibit ACI and ACVI (Taussig et al., 1994) . There could also be RGS proteins in HEK293 cells that do have a significantly differential effect on G␣ o and G␣ i2 (such as RGS6). RGS proteins, receptors, and different adenylyl cyclase subtypes may also colocalize or interact differently with the different G␣ subtypes, allowing for differential effects within the same cell.
The simple collision coupling model we have used was originally formulated for G␣ s -mediated stimulation of adenylyl cyclase (Stickle and Barber, 1992; Whaley et al., 1994) . The model assumes that the G proteins are closely associated with adenylyl cyclase and that agonist potency is independent of G protein and adenylyl cyclase concentrations (Tolkovsky et al., 1982) . On the other hand, there is the possibility that the interaction between the G protein and adenylyl cyclase is transient, so that the kinetics of that encounter need to be considered. A "shuttle mechanism" has been incorporated into the collision coupling model by adding a rate constant for the activation of adenylyl cyclase by G protein and parameters for the number of G proteins and adenylyl cyclase molecules (Krumins et al., 1997) . According to this shuttle mechanism, agonist potency at adenylyl cyclase will be increased by increasing the number of G proteins if the rate of activation of adenylyl cyclase by G protein is fast compared with the rate of inactivation (Krumins et al., 1997) . In this study, we used clones matched for receptor and G␣ protein levels to avoid the possible confound of transient G protein and adenylyl cyclase interactions, although data with different FLAG-G␣ expression levels does suggest that the system is not precoupled. Similar to the present findings, GIRK channel activation by m2 receptor activation of G␣ i2 has also been shown to be consistent with the collision coupling model, whereas m2 activation of GIRK mediated by G␣ o was not (Zhang et al., 2002) . The authors propose that expression conditions were favorable to formation of a precoupled receptor-G␣ o -GIRK channel complex. The possibility of precoupled or colocalized receptor and G protein instead of collision coupling was also indicated by the lack of relationship between agonist potency for inhibition of adenylyl cyclase and the number of 5-HT 1A receptors in NIH-3T 3 cells (Varrault et al., 1992) . In addition, there is evidence for a continuous interaction between ␤-adrenergic receptor and G protein for the stimulation of adenylyl cyclase in turkey erythrocyte membranes (Ugur and Onaran, 1997) . This led to the suggestion that an equilibrium model of G protein and receptor states, such as the extended ternary complex model (Samama et al., 1993) , needs to be considered along with the G protein kinetics of the collision coupling model. This has been done by combining the kinetic parameters of G protein activation and inactivation to the cubic ternary complex model to formulate the cubic ternary complex activation model (Shea et al., 2000) . Unlike the collision coupling model, this more comprehensive model will provide predictions for agonist maximal response and potency in the absence or presence of RGS proteins, whether or not the receptor and G protein are precoupled.
In conclusion, this study demonstrates that the degree of effect of RGS proteins is highly system-dependent on the intrinsic efficacy of the agonist and on tissue factors that govern the efficiency of receptor-G protein-effector coupling. Less efficient systems show a much greater positive regulation by inhibition of RGS protein GAP activity and are consequently more susceptible to negative regulation by RGS proteins. Thus, the determinants of the selectivity of action of RGS proteins are not only their differential tissue distribution (Gold et al., 1997) and selectivity for particular receptor types (Ghavami et al., 2004) but also tissue factors such as levels of receptor, their cognate G protein, and effectors. Consequently, specific modulation of agonist activated G protein kinetics by inhibitors of RGS proteins, now being developed in several laboratories (e.g., Roman et al., 2007) , may prove to be useful adjuncts in specifically enhancing the actions of agonist drugs and endogenous neurotransmitters.
